The data do not suggest that any one ACE inhibitor is better or worse at lowering BP .
ACE inhibitor doses above Max did not significantly lower BP more than Max .
There are no clinical ly meaningful BP lowering differences between different ACE inhibitors .
BACKGROUND ACE inhibitors are widely prescribed for hypertension so it is essential to determine and compare their effects on blood pressure ( BP ) , heart rate and withdrawals due to adverse effects ( WDAE ) .
OBJECTIVES To quantify the dose-related systolic and /or diastolic BP lowering efficacy of ACE inhibitors versus placebo in the treatment of primary hypertension .
Steady‐State Pharmacokinetics and Pharmacodynamics of Cilazapril in the Presence and Absence of Cyclopenthiazide
Summary : Twenty-two patients with essential hypertension received a single dose of 2.5 mg cilazapril and were then r and omised into a double-blind parallel group study to receive either placebo , 1.25 mg cilazapril + 0.5 mg cyclopenthiazide ( CPTZ ) , 2.5 mg cilazapril + 0.5 mg CPTZ , or 2.5 mg cilazapril alone for 1 month . After oral administration of a single dose of 2.5 mg cilazapril , the active diacid cilazaprilat appeared rapidly in the plasma ( Tmax 2.0 ± 0.2 h ) . With the radioinhibitor assay used in this study , a single elimination phase of cilazaprilat was evident , with a half-life ( t1/2 ) of 2–3 h. At steady state , the pharmacokinetics of cilazaprilat were similar to single-dose administration and were not altered by CPTZ . The Cmax and area under the curve ( AUC ) of cilazaprilat were directly proportional to dose . Cilazapril administration in the dose range of 1.25–2.5 mg produced a dose- proportional inhibition of angiotensin-converting enzyme ( ACE ) activity that was maximum 2 h after drug administration . The degree of ACE inhibition correlated with the plasma concentration-time profile of cilazaprilat and the maximum decrease in blood pressure ( BP ) . The EC50 for ACE inhibition by cilazaprilat was 7.7 ng/ml after acute treatment and was not significantly altered during chronic administration or by concomitant administration of CPTZ . There was no evidence of a dose-related anti-hypertensive effect of cilazapril at steady state and , with the small numbers of subjects used in this study , there was no evidence of 24-h BP control with monotherapy
The data do not suggest that any one ACE inhibitor is better or worse at lowering BP .
ACE inhibitor doses above Max did not significantly lower BP more than Max .
There are no clinical ly meaningful BP lowering differences between different ACE inhibitors .
BACKGROUND ACE inhibitors are widely prescribed for hypertension so it is essential to determine and compare their effects on blood pressure ( BP ) , heart rate and withdrawals due to adverse effects ( WDAE ) .
OBJECTIVES To quantify the dose-related systolic and /or diastolic BP lowering efficacy of ACE inhibitors versus placebo in the treatment of primary hypertension .